p-[2-[N-(p-vinylbenzyl)carbamoyl]ethyl]phenyl α-D-mannopyranoside | 359686-30-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: p-[2-[N-(p-vinylbenzyl)carbamoyl]ethyl]phenyl α-D-mannopyranoside
• 英文别名: N-[(4-ethenylphenyl)methyl]-3-[4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]propanamide
• CAS: 359686-30-9
• 化学式: C₂₄H₂₉NO₇
• 分子量: 443.497
• InChiKey: OKRFDMVVXCLATO-AZKGINQHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  129
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  苄基3-(4-羟基苯基)丙酸酯 在 palladium dihydroxide 三氟甲磺酸三甲基硅酯 、 4 A molecular sieve 、 氢气 、 sodium methylate 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 p-[2-[N-(p-vinylbenzyl)carbamoyl]ethyl]phenyl α-D-mannopyranoside
  参考文献：
  名称：

  SYNTHESIS OF NEW GLYCOPOLYMERS CONTAINING β-D-MANNOPYRANOSE, ANDC-2-SUBSTITUTED β-D-MANNOPYRANOSE RESIDUES AS A NEW CLASS OF INHIBITOR

  摘要：

  New styryl monomers containing beta -D-mannopyranose, 2-acetamido-2-deoxy-beta -D-mannopyranose, 2-deoxy-2-fluoro-beta -D-mannopyranose, and 2-deoxy-beta -D-arabino-hexopyranose on their side chains, were efficiently synthesized as a new class of a potent inhibitor resistant to exo-or-mannosidase digestion. The binding affinity of the carbohydrate polymers obtained from those mannopyranosyl styryl monomers by radical polymerization with Concanavalin A were evaluated. A binding assay indicated that the multivalency effect and the affinity enhancement attained by modification at the C-2 position of the beta -D-mannopyranoside residue resulted in the beta -D-mannopyranosyl polymer which has the same affinity as that of the alpha -D-mannopyranosyl polymer.

  DOI：

  10.1081/car-100103953

文献信息

• PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE
  申请人：UNIVERSITE DE MONTREAL

  公开号：EP1948201A1

  公开（公告）日：2008-07-30
• Pharmaceutical Compositions Comprising Polymeric Binders with Non-Hydrolysable Covalent Bonds and Their Use in Treating Celiac Disease
  申请人：Leroux Jean-Christophe

  公开号：US20080254099A1

  公开（公告）日：2008-10-16

  A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.
• US8784792B2
  申请人：——

  公开号：US8784792B2

  公开（公告）日：2014-07-22
• US8883133B2
  申请人：——

  公开号：US8883133B2

  公开（公告）日：2014-11-11
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES LIANTS POLYMÈRES À LIAISONS COVALENTES NON HYDROLYSABLES ET LEUR UTILISATION POUR LE TRAITEMENT DE LA MALADIE COELIAQUE
  申请人：UNIV MONTREAL

  公开号：WO2007053935A1

  公开（公告）日：2007-05-18

  [EN] A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.
  [FR] La présente invention concerne une composition pharmaceutique constituée d'un liant polymère et d'un excipient pharmaceutiquement admis. Ce liant polymère est constitué d'un polymère de synthèse de masse moléculaire élevée dont l'ossature est constituée de liaisons covalentes non hydrolysables. Ce polymère est capable de former des liaisons électrostatiques à un pH inférieur au point isoélectrique du gluten et de ses peptides de dégradation. Ce polymère est en outre capable de se lier au gluten ou à des peptides de dégradation du gluten dans l'appareil gastro-intestinal. L'invention concerne également des procédés d'utilisation du liant polymère pour la liaison au gluten ou à l'un de ses peptides de dégradation, de façon à moins dégrader le gluten en peptides toxiques ou de façon à diminuer l'interaction du gluten, ou de ses peptides de dégradation, avec les muqueuses gastro-intestinales.